BACKGROUND: Long-term outcomes after direct current cardioversion (DCCV) in patients that receive anticoagulation have demonstrated to have no adverse sequela. Less is known about the impact on atrial fibrillation (AF) outcomes and resource utilization of repeated DCCVs that are often required for long-term rhythm control. METHODS: A total of 4,135 AF patients >18 years of age that underwent DCCV with long-term system follow-up were evaluated. Patients were stratified by the number of DCCVs received: 1 (n=2,201), 2-4 (n=1,748), and ≥5 (n=186). Multivariable Cox hazard regression was used to determine the association of DCCV categories to the outcomes of death, AF hospitalization, AF ablation, DCCVs, and stroke/transient ischemic attack. RESULTS: The average follow-up of the patient population was 1,633.1±1,232.9 (median: 1,438.0) days. Patients who underwent 2-4 and ≥5 DCCVs had more comorbidities, namely hypertension, hyperlipidemia and heart failure. Anticoagulation use was common at the time of DCCV in all groups (89.1%, 91.2%, 91.9%, p=0.06) and amiodarone use increased with increasing DCCV category (30.1%, 43.4%, 52.2, p<0.0001). At 5 years, patients that received more DCCVs had higher rates of repeat DCCVs, AF hospitalizations, and ablations. Stroke rates were not increased. Though not statistically significant, 5-year death was increased when comparing DCCV >5 vs. 1, (HR=1.32 [0.89-1.94], p=0.17). CONCLUSIONS: This study found that the increasing number of DCCVs, despite escalation of other pharmacologic and nonpharmacologic therapies, is a long-term independent risk factor for repeat DCCVs, ablations, and AF hospitalizations among AF patients.
BACKGROUND: Long-term outcomes after direct current cardioversion (DCCV) in patients that receive anticoagulation have demonstrated to have no adverse sequela. Less is known about the impact on atrial fibrillation (AF) outcomes and resource utilization of repeated DCCVs that are often required for long-term rhythm control. METHODS: A total of 4,135 AF patients >18 years of age that underwent DCCV with long-term system follow-up were evaluated. Patients were stratified by the number of DCCVs received: 1 (n=2,201), 2-4 (n=1,748), and ≥5 (n=186). Multivariable Cox hazard regression was used to determine the association of DCCV categories to the outcomes of death, AF hospitalization, AF ablation, DCCVs, and stroke/transient ischemic attack. RESULTS: The average follow-up of the patient population was 1,633.1±1,232.9 (median: 1,438.0) days. Patients who underwent 2-4 and ≥5 DCCVs had more comorbidities, namely hypertension, hyperlipidemia and heart failure. Anticoagulation use was common at the time of DCCV in all groups (89.1%, 91.2%, 91.9%, p=0.06) and amiodarone use increased with increasing DCCV category (30.1%, 43.4%, 52.2, p<0.0001). At 5 years, patients that received more DCCVs had higher rates of repeat DCCVs, AF hospitalizations, and ablations. Stroke rates were not increased. Though not statistically significant, 5-year death was increased when comparing DCCV >5 vs. 1, (HR=1.32 [0.89-1.94], p=0.17). CONCLUSIONS: This study found that the increasing number of DCCVs, despite escalation of other pharmacologic and nonpharmacologic therapies, is a long-term independent risk factor for repeat DCCVs, ablations, and AF hospitalizations among AF patients.
Authors: Abdou Elhendy; Federico Gentile; Bijoy K Khandheria; Stephen C Hammill; Bernard J Gersh; Kent R Bailey; Samantha Montgomery; Kelli Burger; James B Seward Journal: Am J Cardiol Date: 2002-01-01 Impact factor: 2.778
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: Ahmad A Elesber; Ana Gabriela Rosales; Regina M Herges; Win-Kuang Shen; Brenda S Moon; Joseph F Malouf; Naser M Ammash; Virend Somers; David O Hodge; Bernard J Gersh; Stephen C Hammill; Paul A Friedman Journal: Eur Heart J Date: 2006-02-02 Impact factor: 29.983
Authors: R Latini; S Masson; S Pirelli; S Barlera; G Pulitano; E Carbonieri; M Gulizia; T Vago; C Favero; D Zdunek; J Struck; L Staszewsky; A P Maggioni; M G Franzosi; M Disertori Journal: J Intern Med Date: 2010-10-22 Impact factor: 8.989
Authors: Mario Talajic; Paul Khairy; Sylvie Levesque; Stuart J Connolly; Paul Dorian; Marc Dubuc; Peter G Guerra; Stefan H Hohnloser; Kerry L Lee; Laurent Macle; Stanley Nattel; Ole D Pedersen; Lynne Warner Stevenson; Bernard Thibault; Albert L Waldo; D George Wyse; Denis Roy Journal: J Am Coll Cardiol Date: 2010-04-27 Impact factor: 24.094
Authors: Scott D Corley; Andrew E Epstein; John P DiMarco; Michael J Domanski; Nancy Geller; H Leon Greene; Richard A Josephson; Joyce C Kellen; Richard C Klein; Andrew D Krahn; Mary Mickel; L Brent Mitchell; Joy Dalquist Nelson; Yves Rosenberg; Eleanor Schron; Lynn Shemanski; Albert L Waldo; D George Wyse Journal: Circulation Date: 2004-03-08 Impact factor: 29.690
Authors: Kevin S Channer; Andrew Birchall; Richard P Steeds; Stephen J Walters; Wilf W Yeo; John N West; Rangasamy Muthusamy; Walter E Rhoden; Basil T Saeed; Phillip Batin; W Paul Brooksby; Ian Wilson; Simon Grant Journal: Eur Heart J Date: 2004-01 Impact factor: 29.983